CLINICAL_TRIALS
trial_result
· 2018-02-06
Clinical Trial Update: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis [Phase 2]
Summary
Phase 2 clinical trial of imatinib mesylate (Gleevec) for systemic sclerosis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hospital for Special Surgery, New York | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2018-02-06